Recursion Pharma

Pharmaceutical development has traditionally focused on intense study and exploitation of an explicit molecular target; this strategy is costly and inefficient. We are revolutionizing drug discovery with a platform that enables us to simultaneously study many diseases and the effects of thousands of drugs on each of them. Our computational platform recognizes thousands of structural changes in tens of thousands of human cells for each disease we model, and then identifies drugs that return those diseased cells to 'normal'. Rather than starting from scratch with novel chemicals, we are exploiting the work of thousands of scientists who have come before us and trying to find new uses for safe molecules they have already designed. We have published our first success in a major scientific journal, in which we used a less powerful pilot platform to identify 2 new possible disease treatments. We are working on 50+ additional diseases now and are in active partnering negotiations.